Page 10 - KIDNEY CANCER
P. 10
Results: Response Rates Secondary Endpoint
Sunitinib Cabozantinib Crizotinib Savolitinib
[n (%)] [n (%)] [n (%)] [n (%)]
Complete Response 0 (0) 2 (5) 0 (0) 0 (0)
Partial Response (PR) 2 (4) 8 (18) 0 (0) 1 (3)
Unconfirmed Partial Response 1 (2) 2 (5) 1 (4) 2 (7)
Stable Disease 23 (50) 23 (51) 7 (25) 8 (28)
Increasing Disease 11 (24) 4 (9) 12 (43) 8 (28)
Symptomatic Deterioration 1 (2) 1 (2) 3 (11) 1 (3)
Early Death 1 (2) 1 (2) 0 (0) 0 (0)
Assessment Inadequate 7 (15) 3 (7) 5 (18) 9 (31)
Total 46 (100) 44 (100) 28 (100) 29 (100)
Confirmed overall response rate with cabozantinib (23%) significantly higher than with sunitinib
(4%) (2-sided P-value= 0.010)
